NPRA Banner

               
Product Search   QUEST3+ System   Enquiries   Sitemap  

Protaxos® (strontium ranelate): New restricted indication and contraindications for use

User Rating: 2 / 5

Star ActiveStar ActiveStar InactiveStar InactiveStar Inactive
 

Date: 13 August 2014

Description: This issue was highlighted in a previous NPCB Safety Alert issued on 27 January 2014. Following completion of NPCB’s benefit-risk profile review related to cardiovascular risk, the indications of Protaxos® have been tightened, and it is contraindicated in patients with established, current or past history of ischaemic heart disease, peripheral artery disease, or those with uncontrolled hypertension. Prescribers are advised to assess and monitor patient’s cardiovascular risk before and during treatment. A Direct Healthcare Professional Communication (DHPC) regarding this issue, along with a Prescriber Checklist, has been approved by NPCB and released by Servier Malaysia Sdn. Bhd.

 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Wednesday 13 November 2024, 12:32:37.

Search

Main Menu English